Mechanisms of RNA-dependent DNA repair in humans

人类 RNA 依赖性 DNA 修复机制

基本信息

项目摘要

Summary of the project DNA double-strand breaks (DSB), the most harmful type of DNA lesions, are faithfully repaired by Homologous recombination (HR). It is universally accepted that HR uses homologous dsDNA as a template for DSB repair. However, recent studies indicate that homologous RNA can also be utilized by HR. RNA may serve as a template for DSB repair or as a primer in the R-loop structure (three-stranded nucleic acid structure consisting of a DNA-RNA hybrid and the displaced ssDNA strand) during restart of DNA replication stalled at DNA lesions. Since ~75% of human genome are capable of being transcribed, RNA may play a significant role in DNA repair. However, very little is known about the mechanisms of RNA-dependent DSB repair by HR. Recently, we and others found that RAD52 protein plays an important role in RNA-dependent DSB repair in yeast and humans. We showed that RAD52 promotes formation of RNA:DNA hybrids through a novel mechanism: inverse RNA strand exchange. In contrast to the conventional (forward) reaction that is initiated at ssDNA to carry out DNA strand exchange with homologous dsDNA, the inverse reaction is initiated at dsDNA containing DSB to carry out strand exchange with homologous RNA (or ssDNA). RAD52-promoted inverse RNA strand exchange is stimulated by Replication Protein A (RPA), a ubiquitous ssDNA binding protein. In addition, our current data indicate that RPA may have a novel direct role in RNA- dependent DSB repair. We found that RPA binds RNA with high affinity in vitro and forms RPA-RNA complexes in human cells. Furthermore, our data show that RPA can promote formation of R-loops in vitro. being the first known protein that possesses this activity. Using biochemical, cellular, single-molecule, and reconstitution approaches we want to understand the mechanisms of RNA-dependent DDB repair promoted by human RAD52 and RPA and its role in genome maintenance. Our AIMs are to study: 1) the mechanism of RAD52-promoted inverse RNA strand exchange and its role in DNA repair and 2) the role of RPA in RNA-dependent DNA repair. The proposed studies are expected to contribute to our understanding of the mechanisms of DNA repair in humans and will help to identify critical functions of RAD52 and RPA in BRCA1/2-deficient tumor cells for development of new cancer therapies.
项目总结

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ALEXANDER V MAZIN其他文献

ALEXANDER V MAZIN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ALEXANDER V MAZIN', 18)}}的其他基金

Small Molecule inhibitors as a new approach to study human RAD51 recombinase
小分子抑制剂作为研究人类 RAD51 重组酶的新方法
  • 批准号:
    10396746
  • 财政年份:
    2021
  • 资助金额:
    $ 45.52万
  • 项目类别:
AML mutation-guided drugging of DNA repair
AML突变引导的DNA修复药物
  • 批准号:
    9885053
  • 财政年份:
    2020
  • 资助金额:
    $ 45.52万
  • 项目类别:
Mechanisms of RNA-dependent DNA repair in humans
人类 RNA 依赖性 DNA 修复机制
  • 批准号:
    10576319
  • 财政年份:
    2020
  • 资助金额:
    $ 45.52万
  • 项目类别:
AML mutation-guided drugging of DNA repair
AML突变引导的DNA修复药物
  • 批准号:
    10543192
  • 财政年份:
    2020
  • 资助金额:
    $ 45.52万
  • 项目类别:
Mechanisms of RNA-dependent DNA repair in humans
人类 RNA 依赖性 DNA 修复机制
  • 批准号:
    10347369
  • 财政年份:
    2020
  • 资助金额:
    $ 45.52万
  • 项目类别:
Small molecule inhibitors as a new approach to study human RAD51 recombinase
小分子抑制剂作为研究人类 RAD51 重组酶的新方法
  • 批准号:
    9762019
  • 财政年份:
    2019
  • 资助金额:
    $ 45.52万
  • 项目类别:
Small molecule inhibitors as a new approach to study human RAD51 recombinase
小分子抑制剂作为研究人类 RAD51 重组酶的新方法
  • 批准号:
    8888191
  • 财政年份:
    2015
  • 资助金额:
    $ 45.52万
  • 项目类别:
Small molecule inhibitors as a new approach to study human RAD51 recombinase
小分子抑制剂作为研究人类 RAD51 重组酶的新方法
  • 批准号:
    9150646
  • 财政年份:
    2015
  • 资助金额:
    $ 45.52万
  • 项目类别:
Identification of inhibitors of RAD54, an important DNA repair protein
重要 DNA 修复蛋白 RAD54 抑制剂的鉴定
  • 批准号:
    8262294
  • 财政年份:
    2012
  • 资助金额:
    $ 45.52万
  • 项目类别:
Development of RAD52 Inhibitors to Induce Lethality of BRCA2-Deficient Cells
开发 RAD52 抑制剂以诱导 BRCA2 缺陷细胞致死
  • 批准号:
    8441581
  • 财政年份:
    2012
  • 资助金额:
    $ 45.52万
  • 项目类别:

相似海外基金

Novel Mechanisms of MED12-TGFbeta-mediated resistance to PARP Inhibitors in BRCA-deficient Cancer Cells
MED12-TGFbeta 介导的 BRCA 缺陷癌细胞对 PARP 抑制剂耐药的新机制
  • 批准号:
    10665588
  • 财政年份:
    2022
  • 资助金额:
    $ 45.52万
  • 项目类别:
Novel Mechanisms of MED12-TGFbeta-mediated resistance to PARP Inhibitors in BRCA-deficient Cancer Cells
MED12-TGFbeta 介导的 BRCA 缺陷癌细胞对 PARP 抑制剂耐药的新机制
  • 批准号:
    10536964
  • 财政年份:
    2022
  • 资助金额:
    $ 45.52万
  • 项目类别:
Carboplatin or Olaparib for BRcA deficient prostate cancer (COBRA)
卡铂或奥拉帕尼治疗 BRcA 缺陷型前列腺癌 (COBRA)
  • 批准号:
    10578711
  • 财政年份:
    2020
  • 资助金额:
    $ 45.52万
  • 项目类别:
Carboplatin or Olaparib for BRcA deficient prostate cancer (COBRA)
卡铂或奥拉帕尼治疗 BRcA 缺陷型前列腺癌 (COBRA)
  • 批准号:
    10417024
  • 财政年份:
    2020
  • 资助金额:
    $ 45.52万
  • 项目类别:
Metabolisms in BRCA-deficient and -proficient ovarian cancer as new therapeutic and diagnostic target.
BRCA 缺乏和丰富的卵巢癌的代谢作为新的治疗和诊断目标。
  • 批准号:
    18K09243
  • 财政年份:
    2018
  • 资助金额:
    $ 45.52万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Targeting BRCA Deficient Cells for Killing
针对 BRCA 缺陷细胞进行杀伤
  • 批准号:
    9114099
  • 财政年份:
    2015
  • 资助金额:
    $ 45.52万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了